TreatSMA

TreatSMA LIVE – A massive success, thank you all

We at TreatSMA would love to thank everyone for participating in Saturdays LIVE SMA DAY. We had a whole array of amazing speakers , sports professionals, worldwide known doctors, professionals in SMA and not forgetting those from the community itself. We also had a few visits from the legendary Geordie sausage!

TreatSMA are extremely proud that the day was such a success. Our team are made up of all volunteers that have a link with SMA, whether that be a parent or someone that directly has SMA themselves.

Big thanks goes to Andi, he truly smashed it!

Thank you for tuning in and we hope to do it again!

Here are the videos. Any questions please do not hesitate to email us.

Love the TreatSMA team.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more